Matteo Piccica, Michele Spinicci, Annarita Botta, Vincenzo Bianco, Filippo Lagi, Lucia Graziani, Alessandro Faragona, Roberto Parrella, Tommaso Giani, Andrea Bartolini, Gianluca Morroni, Mariano Bernardo, Gian Maria Rossolini, Marcello Tavio, Andrea Giacometti, Alessandro Bartoloni
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin with promising activity against most carbapenem-resistant Gram-negative bacteria (CRGNB). However, extensive postmarketing experiences are lacking. This study aimed to analyse the early experience on cefiderocol postmarketing use at three tertiary care hospitals in Italy. METHODS: We retrospectively included patients with infections caused by CRGNB treated with cefiderocol at three Italian tertiary care hospitals from 1 March 2021 to 30 June 2022...
October 9, 2023: Journal of Antimicrobial Chemotherapy